Below are the most recent publications written about "Drug Design" by people in Profiles.
-
Zhang Y, Tang S, Chen T, Mahood E, Vincoff S, Chatterjee P. PeptiVerse: A unified platform for therapeutic peptide property prediction. Nat Commun. 2026 07 16; 17(1).
-
D'Almeida RE, Chen P, Huang Y, Goetz E, Sammeta VR, Yang B, Rao RP, Rasapalli S, Elfawal MA. Design, synthesis, and biological evaluation of a focused pyrrolo- and pyrido-quinazolinone natural products-templated library for anti-fungal and anthelmintic activities. Bioorg Med Chem. 2026 Mar; 134:118517.
-
Chen LT, Quinn Z, Dumas M, Peng C, Hong L, Lopez-Gonzalez M, Mestre A, Watson R, Vincoff S, Zhao L, Wu J, Stavrand A, Schaepers-Cheu M, Wang TZ, Srijay D, Monticello C, Vure P, Pulugurta R, Pertsemlidis S, Kholina K, Goel S, DeLisa MP, Chi JA, Truant R, Aguilar HC, Chatterjee P. Target sequence-conditioned design of peptide binders using masked language modeling. Nat Biotechnol. 2026 Jun; 44(6):1002-1010.
-
Bisht P, Bhattacharya A, Pal A, Singh R, Verma SK. Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: An in silico, in vitro and in vivo approach. Eur J Med Chem. 2025 Feb 05; 283:117160.
-
Tang Q, Khvorova A. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discov. 2024 05; 23(5):341-364.
-
Caldwell TM, Kaufman MD, Wise SC, Mi Ahn Y, Hood MM, Lu WP, Patt WC, Samarakoon T, Vogeti L, Vogeti S, Yates KM, Bulfer SL, Le Bourdonnec B, Smith BD, Flynn DL. Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors. Bioorg Med Chem Lett. 2022 10 15; 74:128929.
-
Zephyr J, Nageswara Rao D, Vo SV, Henes M, Kosovrasti K, Matthew AN, Hedger AK, Timm J, Chan ET, Ali A, Kurt Yilmaz N, Schiffer CA. Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. J Mol Biol. 2022 05 15; 434(9):167503.
-
Funabashi K, Sawata M, Nagai A, Akimoto M, Mashimo R, Takahara H, Kizawa K, Thompson PR, Ite K, Kitanishi K, Unno M. Structures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design. Arch Biochem Biophys. 2021 Sep 15; 708:108911.
-
Verma SK, Verma R, Kumar KSS, Banjare L, Shaik AB, Bhandare RR, Rakesh KP, Rangappa KS. A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies. Eur J Med Chem. 2021 Jul 05; 219:113442.
-
Amcheslavsky A, Wallace AL, Ejemel M, Li Q, McMahon CT, Stoppato M, Giuntini S, Schiller ZA, Pondish JR, Toomey JR, Schneider RM, Meisinger J, Heukers R, Kruse AC, Barry EM, Pierce BG, Klempner MS, Cavacini LA, Wang Y. Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design. Sci Rep. 2021 02 02; 11(1):2751.